What is low-grade intraepithelial neoplasia?
Low-Grade Intraepithelial Neoplasia (LGIN) is a term used in pathology to describe abnormal proliferation of epithelial tissue and is generally considered to be the early stage of precancerous lesions. Such lesions are common in the digestive system (such as esophagus, stomach, colon), cervix, prostate and other organs. The following will provide a detailed analysis of the definition, etiology, diagnosis and treatment.
1. Definition and characteristics of low-grade intraepithelial neoplasia
Low-grade intraepithelial neoplasia refers to abnormal proliferation of epithelial cells that does not yet meet the criteria for malignancy. Its core features include:
| feature | describe |
|---|---|
| cell morphology | Mild atypia, slightly increased nuclear-to-cytoplasmic ratio |
| organizational structure | The glands or epithelium are disorganized but retain some polarity |
| proliferative activity | Ki-67 index is usually lower than high-grade lesions |
| Invasive | No evidence of stromal infiltration |
2. Causes and high-risk factors
The formation of low-grade intraepithelial neoplasia is related to a variety of factors, and the causes of lesions in different parts of the body are different:
| parts | Main risk factors |
|---|---|
| cervix | HPV infection (especially types 16/18), smoking, immunosuppression |
| digestive tract | Helicobacter pylori infection (stomach), Barrett's esophagus (esophagus), chronic inflammation (colon) |
| prostate | Aging and abnormal hormone levels |
3. Diagnostic methods and standards
Diagnosis requires a combination of clinical examination and pathological evaluation:
| Check items | effect |
|---|---|
| endoscopy | Detect suspicious lesions and perform biopsy (such as gastroscopy/enteroscopy) |
| Pathological biopsy | Gold standard, which must comply with WHO classification standards |
| Immunohistochemistry | Auxiliary identification (such as p53, Ki-67 and other markers) |
| Molecular testing | Assessing genetic mutations in specific situations (e.g. TP53) |
4. Treatment and follow-up strategies
The treatment plan needs to be formulated based on the location of the lesion and the individual patient’s condition:
| Treatment | Applicable scenarios |
|---|---|
| Conservative observation | Low-risk lesions, regular endoscopy/cytology review |
| local excision | Endoscopic mucosal resection (EMR) or conization (cervix) |
| pharmacological intervention | Helicobacter pylori eradication (stomach), anti-HPV treatment (cervix) |
| lifestyle adjustments | Quit smoking and supplement antioxidant nutrients (such as vitamin E/C) |
5. Prognosis and Outcome
The risk of progression of low-grade intraepithelial neoplasia varies:
| Influencing factors | progress probability |
|---|---|
| persistent infection | The risk increases 3-5 times when HPV/H. pylori is not cleared |
| Follow-up interval | For those who have not been reviewed for more than 2 years, the rate of malignant transformation can reach 15-20% |
| genetic background | Patients with a family history of cancer have a 2-3 times increased risk |
6. Hotspot correlation analysis of the entire network (last 10 days)
Combined with current medical hotspots, discussions on intraepithelial neoplasia mainly focus on:
1.Breakthrough in early screening technology: New progress in the application of liquid biopsy in the detection of precancerous lesions
2.AI-assisted diagnosis: The deep learning model’s recognition accuracy for low-level lesions reaches 92% (latest research in a sub-journal of "Nature")
3.patient education needs: Baidu Health data shows that the search volume for "intraepithelial neoplasia" increased by 37% week-on-week.
4.treatment controversy: Some experts recommend reclassifying certain low-risk LGINs as benign lesions
In summary, low-grade intraepithelial neoplasia is a pathological condition that requires attention but does not require excessive panic. Standardized monitoring and individualized intervention can effectively block its progression to malignant tumors. It is recommended that high-risk groups regularly participate in relevant cancer screening programs to achieve early diagnosis and early treatment.
check the details
check the details
en
